2018 Webinar: HBV - Update on the Guidelines and Controversies in Management

4.4 (10 votes)

Recorded On: 10/24/2018

This webinar focuses on reviewing the highlights of the revised AASLD Clinical Practice Guidelines for HBV infection in the first talk.  The second presentation addresses a key area of controversy, namely the role of antiviral therapy in patients during the immunotolerant phase of chronic HBV infection.

Marc G. Ghany (Moderator)

Marc G. Ghany, MD, MHSc, FAASLD is an Investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis. 

 

Norah A. Terrault

Norah A. Terrault, MD, MPH, FAASLD is a Professor of Medicine and Chief of Gastroenterology and Liver Diseases at the Keck School of Medicine at University of Southern California. She received her MD from the University of Alberta and completed fellowships in Internal Medicine and Gastroenterology at the University of Toronto and a master’s in public health at the University of California at Berkeley. 

Dr. Terrault has focused her clinical and research activities on viral hepatitis and non-alcoholic fatty liver disease, especially in special populations including those with cirrhosis and those with transplants. In addition to multiple clinical trials related to preventing and treating chronic hepatitis viral hepatitis and fatty liver, Dr. Terrault has been PI on multiple NIH-funded studies, including the current NIH-supported HBV clinical research network (HBRN) and nonalcoholic steatohepatitis clinical research network (NASH CRN). She has authored 330 peer-reviewed manuscripts, editorials, invited reviews as well as US national guidelines for treatment of chronic hepatitis B and C. She is past associate editor for Hepatology and deputy editor for Liver Transplantation and co-edited Zakim and Boyer’s textbook in hepatology. 

Dr. Terrault is the founder of ECHO-Plus, a multifaceted program to train and support primary care physicians in California to care for patients with hepatitis. She has a long history of mentoring fellows and junior faculty in clinical research and is passionate about creating research support and opportunities for the next generation of GI/Hepatology investigators. Dr. Terrault was recently elected as Councilor to the AASLD governing board and will serve as president in 2023.

Kosh Aggarwal

Dr. Kosh Agarwal is a Consultant Hepatologist and Transplant Physician at the Institute of Liver Studies, King’s College Hospital. Dr Agarwal is the Lead for the Kings Viral Hepatitis Service, the largest treatment centre for viral hepatitis in the UK. In 1991 Dr Agarwal graduated from Newcastle University and his postgraduate training was undertaken in Newcastle with the majority of his clinical and research training at the Regional Liver and Transplant Unit. Prior to his appointment at King’s, Dr Agarwal was a consultant and honorary senior lecturer at the Regional Liver and Transplant Unit in Newcastle. He also spent a year at the Division of Liver Diseases, Mount Sinai, New York, USA. Dr Agarwal is an investigator for several ongoing studies evaluating the safety and efficacy of various antiviral treatment regimens for chronic Hepatitis B and C. He is a member of the EASL, AASLD, BASL, & ILTS.

Key:

Complete
Failed
Available
Locked
HBV - Update on the Guidelines and Controversies in Management
Open to view video.
Open to view video.